PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Aug 13, 2025
Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI
Read more at globenewswire.com
